Cerebral small vessel disease-induced apolipoprotein e leakage is associated with alzheimer disease and the accumulation of amyloid β-protein in perivascular astrocytes

Journal of Neuropathology and Experimental Neurology

Volumn 67, Issue 9, 2008, Pages 842-856

  Utter, Sabrina ^a   Tamboli, Irfan Y ^a   Walter, Jochen ^a   Upadhaya, Ajeet Rijal ^b   Birkenmeier, Gerd ^c   Pietrzik, Claus U ^d   Ghebremedhin, Estifanos ^e   Thal, Dietmar Rudolf ^a,b  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

^e GOETHE UNIVERSITY   (Germany)

Author keywords

Alzheimer disease; Amyloid A protein; Apolipoprotein E; Astrocytes; Blood brain barrier; Small vessel disease

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; IMMUNOGLOBULIN G; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ANTIBODY DETECTION; ARTICLE; ASTROCYTE; BASAL GANGLION; BLOOD VESSEL WALL; BRAIN ARTERY; BRAIN BLOOD VESSEL; BRAIN REGION; BRAIN TISSUE; CARBOXY TERMINAL SEQUENCE; CEREBRAL SMALL VESSEL DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MICROANGIOPATHY; NEUROPIL; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CONTENT; PROTEIN DETERMINATION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; WESTERN BLOTTING; BLOOD BRAIN BARRIER; BLOOD VESSEL; BRAIN; IMMUNOHISTOCHEMISTRY; METABOLISM; MIDDLE AGED; PATHOLOGY; VASCULAR AMYLOIDOSIS; VASCULARIZATION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; APOLIPOPROTEINS E; ASTROCYTES; BLOOD VESSELS; BLOOD-BRAIN BARRIER; BLOTTING, WESTERN; BRAIN; CEREBRAL AMYLOID ANGIOPATHY; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; LDL-RECEPTOR RELATED PROTEIN 1; MALE; MIDDLE AGED;

EID: 52649157170     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/NEN.0b013e3181836a71     Document Type: Article

References (73)

1. Alzheimer A. Ueber eine eigenartige Erkrankung der Hirnrinde. Allg Zschr Psych 1907;64:146-48
2. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991;82:239-59
3. Masters CL, Simms G, Weinman NA, et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A 1985;82:4245-49
4. Games D, Adams D, Alessandrini R, et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995;373:523-27
5. Hsiao K, Chapman P, Nilsen S, et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996;274: 99-102
6. Iwata N, Tsubuki S, Takaki Y, et al. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition. Nat Med 2000;6: 143-50
7. Sturchler-Pierrat C, Abramowski D, Duke M, et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Proc Natl Acad Sci U S A 1997;94:13287-92
8. Weller RO, Massey A, Newman TA, et al. Cerebral amyloid angiopathy: Amyloid beta accumulates in putative interstitial fluid drainage pathways in Alzheimer's disease. Am J Pathol 1998;153:725-33
9. Zlokovic BV. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci 2005;28:202-8
10. Mann DM, Iwatsubo T, Cairns NJ, et al. Amyloid beta protein (Abeta) deposition in chromosome 14-linked Alzheimer's disease: Predominance of Abeta42(43). Ann Neurol 1996;40:149-56
11. Mehta ND, Refolo LM, Eckman C, et al. Increased Abeta42(43) from cell lines expressing presenilin 1 mutations. Ann Neurol 1998;43: 256-58
12. Akiyama H, Schwab C, Kondo H, et al. Granules in glial cells of patients with Alzheimer's disease are immunopositive for C-terminal sequences of beta-amyloid protein. Neurosci Lett 1996;206:169-72
13. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-77
14. Funato H, Yoshimura M, Yamazaki T, et al. Astrocytes containing amyloid beta-protein (Abeta)-positive granules are associated with Abeta40-positive diffuse plaques in the aged human brain. Am J Pathol 1998;152:983-92
15. Thal DR, Hartig W, Schober R. Diffuse plaques in the molecular layer show intracellular A beta(8-17)-immunoreactive deposits in subpial astrocytes. Clin Neuropathol 1999;18:226-31
16. Yamaguchi H, Sugihara S, Ogawa A, et al. Diffuse plaques associated with astroglial amyloid beta protein, possibly showing a disappearing stage of senile plaques. Acta Neuropathol (Berl) 1998;95:217-22
17. Wyss-Coray T, Loike JD, Brionne TC, et al. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat Med 2003;9:453-57
18. Leissring MA, Farris W, Chang AY, et al. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 2003;40:1087-93
19. Mahley RW. Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science 1988;240:622-30
20. Brecht WJ, Harris FM, Chang S, et al. Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. J Neurosci 2004;24:2527-34
21. Pitas RE, Boyles JK, Lee SH, et al. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim Biophys Acta 1987;917:148-61
22. Thal DR, Larionov S, Abramowski D, et al. Occurrence and colocalization of amyloid beta-protein and apolipoprotein E in perivascular drainage channels of wild-type and APP-transgenic mice. Neurobiol Aging 2007;28:1221-30
23. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-23
24. Sadowski M, Pankiewicz J, Scholtzova H, et al. A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates betaamyloid toxicity and fibril formation in vitro and reduces betaamyloid plaques in transgenic mice. Am J Pathol 2004;165:937-48
25. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: High-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A 1993;90:1977-81
26. Rebeck GW, Reiter JS, Strickland DK, Hyman BT. Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions. Neuron 1993;11:575-80
27. Koistinaho M, Lin S, Wu X, et al. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med 2004;10:719-26
28. Calhoun ME, Burgermeister P, Phinney AL, et al. Neuronal overexpression of mutant amyloid precursor protein results in prominent deposition of cerebrovascular amyloid. Proc Natl Acad Sci U S A 1999; 96:14088-93
29. Brun A, Englund E. A white matter disorder in dementia of the Alzheimer type: A pathoanatomical study. Ann Neurol 1986;19:253-62
30. Thal DR, Ghebremedhin E, Orantes M, Wiestler OD. Vascular pathology in Alzheimer's disease: Correlation of cerebral amyloid angiopathy and arteriosclerosis/lipohyalinosis with cognitive decline. J Neuropathol Exp Neurol 2003;62:1287-301
31. Kalaria RN, Ballard C. Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord 1999;13:S115-S23
32. Skoog I, Kalaria RN, Breteler MM. Vascular factors and Alzheimer disease. Alzheimer Dis Assoc Disord 1999;13:S106-S14
33. Scholler K, Trinkl A, Klopotowski M, et al. Characterization of microvascular basal lamina damage and blood-brain barrier dysfunction following subarachnoid hemorrhage in rats. Brain Res 2007;1142: 237-46
34. Nag S, Robertson DM. The brain in hypertension. In: Kalimo H, ed. Pathology & Genetics: Cerebrovascular Diseases. Basel, Switzerland: ISN Neuropath Press, 2005;286-92
35. Thal DR, Schultz C, Botez G, et al. The impact of argyrophilic grain disease on the development of dementia and its relationship to concurrent Alzheimer's disease-related pathology. Neuropathol Appl Neurobiol 2005;31:270-79
36. Hughes CP, Berg L, Danziger WL, et al. A new clinical scale for the staging of dementia. Br J Psychiatry 1982;140:566-72
37. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington DC: American Psychiatric Association, 1994
38. The National Institute on Aging, and Reagan Institute Working Group. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer's disease. Neurobiol Aging 1997;18:S1-S2
39. Insausti R, Amaral DG. Hippocampal formation. In: Paxinos G, Mai JK, eds. The Human Nervous System. 2nd ed. London, England: Elsevier 2004:872-914
40. Braak H, Braak E. Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol 1991;1:213-16
41. Iqbal K, Braak H, Braak E, Grundke-Iqbal I. Silver labeling of Alzheimer neurofibrillary changes and brain beta-amyloid. J Histotechnol 1993;16: 335-42
42. Braak H, Braak E. The human entorhinal cortex: Normal morphology and lamina-specific pathology in various diseases. Neurosci Res 1992; 15:6-31
43. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-86
44. Thal DR, Rüb U, Schultz C, et al. Sequence of Abeta-protein deposition in the human medial temporal lobe. J Neuropathol Exp Neurol 2000;59: 733-48
45. Thal DR, Rüb U, Orantes M, Braak H. Phases of Abeta-deposition in the human brain and its relevance for the development of AD. Neurology 2002;58:1791-800
46. Vonsattel JP, Myers RH, Hedley-Whyte ET, et al. Cerebral amyloid angiopathy without and with cerebral hemorrhages: A comparative histological study. Ann Neurol 1991;30:637-49
47. Pietrzik CU, Busse T, Merriam DE, et al. The cytoplasmic domain of the LDL receptor-related protein regulates multiple steps in APP processing. EMBO J 2002;21:5691-700
48. Wenham PR, Price WH, Blandell G. Apolipoprotein E genotyping by one-stage PCR. Lancet 1991;337:1158-59
49. Ghebremedhin E, Braak H, Braak E, Sahm J. Improved method facilitates reliable APOE genotyping of genomic DNA extracted from formaldehyde- fixed pathology specimens. J Neurosci Methods 1998;79:229-31
50. Thal DR, Capetillo-Zarate E, Larionov S, et al. Capillary cerebral amyloid angiopathy is associated with vessel occlusion and cerebral blood flow disturbances. Neurobiol Aging. 2008 [Epub ahead of print]
51. Thal DR, Schultz C, Dehghani F, et al. Amyloid beta-protein (Abeta)-containing astrocytes are located preferentially near N-terminal-truncated Abeta deposits in the human entorhinal cortex. Acta Neuropathol (Berl) 2000;100:608-17
52. Namba Y, Tomonaga M, Kawasaki H, et al. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt- Jakob disease. Brain Res 1991;541:163-66
53. Sagare A, Deane R, Bell RD, et al. Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med 2007;13:1029-31
54. Ito S, Ohtsuki S, Kamiie J, et al. Cerebral clearance of human amyloid-beta peptide (1-40) across the blood-brain barrier is reduced by self-aggregation and formation of lowdensity lipoprotein receptorrelated protein-1 ligand complexes. J Neurochem 2007;103: 2482-90
55. Quinn KA, Grimsley PG, Dai YP, et al. Soluble low density lipoprotein receptor-related protein (LRP) circulates in human plasma. J Biol Chem 1997;272:23946-51
56. Huang Y, Liu XQ, Wyss-Coray T, et al. Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons. Proc Natl Acad Sci U S A 2001;98: 8838-43
57. Bales KR, Verina T, Dodel RC, et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet 1997; 17:263-64
58. Gallardo G, Schluter OM, Sudhof TC. A molecular pathway of neurodegeneration linking alpha-synuclein to ApoE and Abeta peptides. Nat Neurosci 2008;11:301-8
59. Greenow K, Pearce NJ, Ramji DP. The key role of apolipoprotein E in atherosclerosis. J Mol Med 2005;83:329-42
60. Yip AG, McKee AC, Green RC, et al. APOE, vascular pathology, and the AD brain. Neurology 2005;65:259-65
61. Ishigami M, Swertfeger DK, Hui MS, et al. Apolipoprotein E inhibition of vascular smooth muscle cell proliferation but not the inhibition of migration is mediated through activation of inducible nitric oxide synthase. Arterioscler Thromb Vasc Biol 2000;20:1020-26
62. Zhu Y, Hui DY. Apolipoprotein E binding to low density lipoprotein receptor-related protein-1 inhibits cell migration via activation of cAMP-dependent protein kinase A. J Biol Chem 2003;278:36257-63
63. Alafuzoff I, Adolfsson R, Grundke-Iqbal I, Winblad B. Blood-brain barrier in Alzheimer dementia and in non-demented elderly. An immunocytochemical study. Acta Neuropathol 1987;73:160-66
64. Alafuzoff I, Adolfsson R, Grundke-Iqbal I, Winblad B. Perivascular deposits of serum proteins in cerebral cortex in vascular dementia. Acta Neuropathol 1985;66:292-98
65. Ishii T, Haga S, Shimizu F. Identification of components of immunoglobulins in senile plaques by means of fluorescent antibody technique. Acta Neuropathol 1975;32:157-62
66. Zipser BD, Johanson CE, Gonzalez L, et al. Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol Aging 2007;28:977-86
67. Clifford PM, Zarrabi S, Siu G, et al. Abeta peptides can enter the brain through a defective blood-brain barrier and bind selectively to neurons. Brain Res 2007;1142:223-36
68. Namba Y, Tsuchiya H, Ikeda K. Apolipoprotein B immunoreactivity in senile plaque and vascular amyloids and neurofibrillary tangles in the brains of patients with Alzheimer's disease. Neurosci Lett 1992;134: 264-66
69. Gentile MT, Poulet R, Pardo AD, et al. beta-Amyloid deposition in brain is enhanced in mouse models of arterial hypertension. Neurobiol Aging 2007 [Epub ahead of print]
70. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 1992;258:468-71
71. Donahue JE, Johanson CE. Apolipoprotein E, amyloid-beta, and blood-brain barrier permeability in Alzheimer disease. J Neuropathol Exp Neurol 2008;67:261-70
72. Fullerton SM, Shirman GA, Strittmatter WJ, Matthew WD. Impairment of the blood-nerve and blood-brain barriers in apolipoprotein e knockout mice. Exp Neurol 2001;169:13-22
73. Morris JC. The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 1993;43:2412-14